Each Year, an Estimated 600 People Are Diagnosed With Adrenocortical Carcinoma Bolstering Growth of the Adrenocortical Carcinoma Treatment Market

 

Adrenocortical Carcinoma Treatment Market

In January 2019, Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, has announced the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma. 

The high prevalence of adrenal cortical carcinoma is a prime factor contributing to the growth of the adrenocortical carcinoma treatment market. According to the American Society of Clinical Oncology (ASCO), each year, an estimated 600 people are diagnosed with adrenocortical carcinoma. This type of cancer is much less common than an adrenal adenoma, a benign tumor that is found most commonly in middle-aged and older adults. The average age of a person diagnosed with an adrenal gland tumor is 46. Advancement in the diagnosing and treatment of adrenocortical carcinoma is again fostering the growth of the adrenocortical carcinoma treatment market.

What is Adrenocortical Carcinoma and various treatment available in the market?

Adrenocortical carcinoma is the most common form of cancer that begins in the adrenal gland, a small organ at the base of the kidneys. The adrenal glands produce hormones such as cortisol, adrenaline, and hydrocortisone. Adrenal tumors can be either malignant (which has to be treated) or benign (which does not have to be treated if it is not malignant). Treatment for adrenocortical carcinoma can be via surgery, chemotherapy, radiation therapy, or immunotherapy. Chemotherapy often uses a combination of drugs to target and destroy the tumor and any secondary tumors. Radiation therapy is used to target the cancer cells and may also require surgery, depending on the type of radiation used. Immunotherapy is used to suppress the immune system's ability to fight off the disease and may require a series of injections of medicine to achieve the full effect.

From the geographical perspective, North America is expected to dominate the global adrenocortical carcinoma treatment market and this can be accredited to the continuous FDA approval for such cancer treatment. For example, in July 2018, The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable).

 

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more